Share Name Share Symbol Market Type Share ISIN Share Description
Kromek LSE:KMK London Ordinary Share GB00BD7V5D43 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  +0.00p +0.00% 19.875p 19.75p 20.00p 19.875p 19.875p 19.875p 2,518.00 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 8.3 -4.1 -1.5 - 30.91

Kromek (KMK) Latest News

More Kromek News
Kromek Takeover Rumours

Kromek (KMK) Share Charts

1 Year Kromek Chart

1 Year Kromek Chart

1 Month Kromek Chart

1 Month Kromek Chart

Intraday Kromek Chart

Intraday Kromek Chart

Kromek (KMK) Discussions and Chat

Kromek Forums and Chat

Date Time Title Posts
17/1/201714:10Kromek Group PLC753.00
19/5/201507:23Kromek Group (KMK) - Overvalued AIM mugging177.00

Add a New Thread

Kromek (KMK) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
18/01/2017 17:40:0619.5050,0009,750.00O
18/01/2017 16:25:4719.7510,0001,975.30O
18/01/2017 13:43:5519.855,4821,088.18O
18/01/2017 11:48:2319.7512,0002,370.36O
View all Kromek trades in real-time

Kromek (KMK) Top Chat Posts

Kromek Daily Update: Kromek is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker KMK. The last closing price for Kromek was 19.88p.
Kromek has a 4 week average price of 21.05p and a 12 week average price of 24.05p.
The 1 year high share price is 36p while the 1 year low share price is currently 18.50p.
There are currently 155,521,082 shares in issue and the average daily traded volume is 224,685 shares. The market capitalisation of Kromek is £30,909,815.05.
culford: 2nd half normally better than 1st half and very good order book now. If a massive order comes in should be able to get finance to assist fulfilling it. It is v tight though and share price does not feel good. If they prove don't need cash this share should double v quickly though.
2niffy: Company is burning through cash. Any significant order would require an increase in working cap, mobilisation costs etc which are not factored into brokers forecasts. Customer unlikely to place order without surety of companies financial strength. Refinancing required. Could be done in various ways but probably via institutional placing with private clients getting diluted out of sight. Their last fundraising at 25p a circ 30% discount to the then prevailing share price. Miton in strong position to dictate terms re financing and a lower share price strengthens their hand.
quepassa: yes, very convincing......"Tumps focus on homland" let's be realistic, their sales are pretty microscopic and management do not convince in my opinion. Kromek have been back to the equity trough once or twice already and they have tested the faith of investors by issuing a shock warning on sales just a few months after flotation and now won't even give chapter and verse on their 4/4/14 RNS announcement about the mega $159million contract. Where are the sales for the airport scanners, the medical imaging equipment which were so much spoken of? We hear repeatedly about a series of smallish contracts from Darpa for some cheap-to-buy handheld devices but what about the big ticket medical imaging equipment and the high-spec security scanning equipment. What about sales for that? I personally can understand the share price slipping and the market becoming disenchanted. There is a big gulf in my opinion between the talk and the walk at Kromek. Don't blame Amphion for share price weakness because if Kromek were so attractive, some institution would have bitten Amphion's arm off to acquire their full position. Good luck all but carefully weigh reality against over zealous expectations. ALL IMO. DYOR. QP
culford: Bapodra, Valuation of loss making companies is difficult. You suggest £20m maximum and I would be interested in why? Is that a suitable discount to the net assets of £24m? Or is it 2.5x historic sales? The market is always right on any day and my interest is whether its worth buying or selling on a longer term view. My thought process is as follows. With KMK, there is enough evidence to show that sales will grow substantially, probably to >$100m per annum in due course. A company trades at a multiple of sales according to its margin and growth rate. A mature company with 10% margin will trade at c1x sales. KMK is fast growing and has high margins and I believe should trade on c5x sales - this would be 5x £9m this year and 5x £12m next year taking the consensus forecasts. That would be market cap of £45m rising to £60m or 29p share price rising to 38p. At any stage in this next 18 months it could get an order worth >£12m per annum, which would at least double that 38p to 76p. Thus in my view, buying KMK is at a 45% discount to next year's fundamental value on basis of no big contracts coming in. If and when they come in, I will at least triple my money.
bapodra_investments: Based on the market cap of around £35m, how can this be justified based on it's current annual turnover and current gross profits or lack of! This is why the share price has been on a severe downtrend over the past 12 months. Just look at the charts they do not lie. The IPO price for Kromek was way overvalued and investors got sucked in. Even now this company is overvalued based on current financials. This should not have a market cap of more than £20m in my opinion and therefore the price still has to go down. However should it increase its revenues significantly then things may change. The key point is that these contracts sound really big but when you annualise them and actually assess how much will be shown in a set of annual accounts then they do not sound as significant or meaningful as we are led to believe and therefore the market cap cannot be justified in anyway.
culford: QP KMK has disappointed the markets and its share price is languishing accordingly. In year to April 13 its revenues were £2.7m and in year to April 16 its revenues were £8.3m - a growth of threefold over three years. In the last year, when it attracted Sir Peter Williams to become its Chairman, its orders received were $30m, or c£24m, but these will be received over multiple years. In the current year, sales will be marginally higher at c£9m. In the past year it has become sole supplier to Darpa, the US agency to which it has supplied >$6m of sales. Darpa has said that it will increase the size of its nuclear detection tests (which need KMK's devices) in 2017 before rolling this out to c15 US cities in 2018. See last news: KMK will receive orders of c$10m for each city so that is orders of c$150m to be received from end of 2017 for 2018 and beyond. In October it received orders for a military solution for the US and UK military, which will be of similar scale and slightly later timing. Thus whilst i share your disappointment on the share performance, you cannot say that there is a diminutive growth in sales and the potential growth can be checked from third party sources.
daz: The announcement today further underpins the revenue forecast for this financial year. Any more contract announcements in the next few months and I think we will be seeing upgrades and the share price should follow.
bapodra_investments: I mean just look at the charts (above). It speaks volumes! There is more volume coming out of the charts than any buying or selling volume on this stock. Can anyone offer a seriously credible reason why the price action is not extremely positive on this stock? Can anyone offer a credible argument as to why this share price is not going upwards? Have a look at below which is from Proactive Investors today: ------------------------------------------------------------------------------------ Tech company investor Amphion Innovations Plc (LON:AMP) has drawn a further US$1.77mln from a loan facility secured against its holdings in Aim-listed Kromek (LON:KMK) and Motif Bio (LON: MTFB). Interest on the new funds will be a rate of 10% annually with repayments starting on 1 May and the final repayment due on 1 February. The facility was set up just under two years ago with a maximum draw down of US$10mln. The latest loan tranche will be used for working capital. It is secured on 7.77mln shares of Kromek and 14.9mln shares of Motif Bio. Richard Morgan, Amphion’s chief executive, said: "We continue to believe in the future upside potential of our holdings in both partner companies, Kromek and Motif Bio. “We are working on moving other programmes forward and this facility gives us access to additional working capital to progress the business' pipeline while these two partner companies develop further." Graham Lumsden, CEO of Motif Bio, said: "We welcome Amphion's continued commitment as a shareholder in Motif Bio." ------------------------------------------------------------------------------------ There is a big clue (above) for those savy investors who will realise what may be happening.
bapodra_investments: Can anyone explain why the dire share price performance over the past several months then? This must have all been priced in and therefore Kromek became overpriced! It always worries me when a share price does not react to positive news in a proportionate manner.
bapodra_investments: The DARPA deal has not made a difference to the share price. Now this concerns me. Bearing in mind that the stock market is a forward pricing mechanism looking say 6 months ahead then the fact the share price has not gone up tells me that revenue disability going forward is still a concern.
Kromek share price data is direct from the London Stock Exchange
Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:40 V: D:20170119 10:56:06